Reproductive Health

Prevalence of sexually transmitted infections among pregnant women with known HIV status in northern Tanzania
Sia E Msuya*,1,2,4, Jacqueline Uriyo1,4, Akhtar Hussain1, Elizabeth M Mbizvo1,5, Stig Jeansson3, Noel E Sam4 and Babill Stray-Pedersen2

Address: 1Department of International Health, Institute of General Practice and Community Medicine, University of Oslo, Oslo, Norway, 2Department of Obstetric and Gynecology, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway, 3Department of Microbiology, Ulleval University Hospital, University of Oslo, Oslo, Norway, 4Kilimanjaro Christian Medical Centre, Moshi, Tanzania and 5Ministry of Health and Child Welfare, Harare, Zimbabwe

Email: Sia E Msuya* - siamsuya@hotmail.com; Jacqueline Uriyo - jackieuriyo@yahoo.com; Akhtar Hussain - akhtar.hussain@medisin.uio.no; Elizabeth M Mbizvo - embizvo@mweb.co.zw; Stig Jeansson - s.l.jeansson@medisin.uio.no; Noel E Sam - noelsam@kcmc.ac.tz; Babill Stray-Pedersen - babill.stray-pedersen@medisin.uio.no

* Corresponding author

Abstract

Objectives: To determine the prevalence of sexually transmitted infections (STIs) and other reproductive tract infections (RTIs) among pregnant women in Moshi, Tanzania and to compare the occurrence of STIs/RTIs among human immunodeficiency virus (HIV)-infected and uninfected women.

Methods: Pregnant women in their 3rd trimester (N = 2654) were recruited from two primary health care clinics between June 2002 and March 2004. They were interviewed, examined and genital and blood samples were collected for diagnosis of STIs/RTIs and HIV.

Results: The prevalence of HIV, active syphilis and herpes simplex virus – type 2 (HSV-2) were 6.9%, 0.9% and 33.6%, respectively, while 0.5% were positive for \textit{N} gonorrhoeae, 5.0% for \textit{T} vaginalis and 20.9% for bacterial vaginosis. Genital tract infections were more prevalent in HIV-seropositive than seronegative women, statistically significant for syphilis (3.3% vs 0.7%), HSV-2 (43.2% vs 32.0%), genital ulcers (4.4% vs 1.4%) and bacterial vaginosis (37.2% vs 19.6%). In comparison with published data, a declining trend for curable STIs/RTIs (syphilis, trichomoniasis and bacterial vaginosis) was noted.

Conclusion: Rates of STIs and RTIs are still high among pregnant women in Moshi. Where resources allow, routine screening and treatment of STIs/RTIs in the antenatal care setting should be offered. Higher STIs/RTIs in HIV-seropositive women supports the expansion of HIV-counseling and testing services to all centers offering antenatal care. After identification, STIs/RTIs need to be aggressively addressed in HIV-seropositive women, both at antenatal and antiretroviral therapy care clinics.

Published: 25 February 2009

Reproductive Health 2009, 6:4 doi:10.1186/1742-4755-6-4

Received: 24 October 2008 Accepted: 25 February 2009

This article is available from: http://www.reproductive-health-journal.com/content/6/1/4

© 2009 Msuya et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Sexually transmitted infections (STIs) are a major public health problem, especially in developing countries [1,2]. They are highly prevalent among pregnant women in Africa and cause significant maternal and perinatal morbidity [2-6]. STIs and other reproductive tract infections (RTIs) have been associated with a number of adverse pregnancy outcomes including abortion, stillbirth, pre-term delivery, low birth weight, postpartum sepsis, neonatal pneumonia, neonatal blindness & congenital infection [1-2]. In addition, STIs/RTIs have been shown to facilitate transmission of HIV [7-12]. The control of STIs/RTIs, especially in pregnancy, is thus a priority, particularly in resource-poor settings where they are prevalent.

The prevalence of STIs however, has been shown to vary from one country to another and among different groups within the same country [2]. In Tanzania, the difference of STI/RTI prevalence by region, population and time-period has been observed [3,6,13-18]. There is thus a need to have local knowledge of the epidemiology of STIs/RTIs by periodically monitoring the prevalence of etiological agents. This information is useful in guiding clinical management, treatment protocols and to form the basis for STI surveillance. In this paper we report the prevalence of STIs/RTIs among pregnant women attending routine antenatal care in Moshi urban, Tanzania, as well as comparing the occurrence of infections among HIV-seropositive and sero-negative women. In addition, we compared the results of this study with previous published data on the prevalence of sexually transmitted infections among pregnant women in the same clinics.

To simplify the reading of the text, the acronym RTIs is used exclusively and is to be understood to include STIs as well as other non sexually transmitted diseases of the reproductive tract (i.e. bacterial vaginosis and candidiasis).

Methods
Study sites and population
The study was conducted among pregnant women attending routine antenatal care at two of the largest primary health care clinics (PHC) (Majengo and Pasua) in Moshi urban district. The district is the capital of Kilimanjaro region, situated in Northern Tanzania with the population of about 230,000 people [19]. The two clinics are the largest PHC and also represent women from the largest urban district. The district is the capital of Kilimanjaro. The two clinics are the largest PHC and also represent women from the largest region, situated in Northern Tanzania with the population of about 230,000 people [19]. The two clinics are the largest PHC and also represent women from the largest region, situated in Northern Tanzania with the population of about 230,000 people [19].

Approval for the study was obtained from the Tanzanian Ministry of Health and The Regional Committee for Medical Research Ethics; Region III (Regional komite for forskninsetikk region III)

Laboratory methods
Active syphilis was diagnosed by positive results of both the rapid plasma regain test (RPR; Becton Dickinson, MD, USA) and a specific test, Determine Syphilis TP (Abbott Laboratories, IL, USA). HSV-2 was detected by the type-specific HSV-2 ELISA test (Focus Diagnostics, Cypress, California USA). HIV was diagnosed by a positive result
on both the Determine HIV 1/2 (Abbott Laboratories, IL, USA) and Capillus HIV 1/2 (Trinity Biotech, Ireland). Discordant results (< 1%) were resolved by an ELISA test, Vironostika HIV Uni-form II (Organon Teknika, Boxtel, Netherlands). IgG antibodies to *Chlamydia trachomatis* was assessed in serum by an ELISA test (Ani Labsystems Ltd, Finland).

Trichomoniasis was diagnosed using wet preparation, candidiasis by visual inspection of *Candida* species on potassium hydroxide (KOH) preparations or on Gram-stained vaginal swabs. Bacterial vaginosis was diagnosed on the basis of Amsel's criteria [20]. *N. gonorrhoeae* was diagnosed by culture (modified Thayer-Martin medium) and/or positive Gram-stained of endocervical swabs for Gram-negative diplococci.

**Statistical analysis**

The data were entered and analyzed using SPSS statistical software, version 12.0 (SPSS, Chicago, IL, USA). Descriptive statistics were obtained through frequencies and cross tabulations. Comparison between groups was made using the χ² tests and Fisher exact test when appropriate. All analyses were two-tailed and the level of significance was set at 5%.

**Results**

The age of the 2654 participating women ranged from 14–43 years (median 24 years), parity from 0–9 (median 1) and gestation age from 28–40 weeks (median 30 weeks). Other demographic details are described in Table 1.

The prevalence of laboratory diagnosed RTIs by HIV status is shown in Table 2. Seven percent of the women had HIV infection, 0.9% had active syphilis, 33.6% were HSV-2 positive and 17.5% had IgG antibodies for *C. trachomatis*. The prevalence of *N. gonorrhoeae* was low (0.5%) while 23.9% of the women had trichomoniasis and/or bacterial vaginosis.

Except for candidiasis, the prevalence of both viral and bacterial RTIs were higher in HIV-seropositive women than in the HIV-seronegative women, significantly for syphilis (p < 0.001), HSV-2 (p = 0.03), gonorrhoea (p = 0.05), Chlamydia trachomatis Ab (p = 0.004), bacterial vaginosis (p < 0.001) and genital ulcers (p = 0.002), Table 2.

Table 3 shows a comparison of RTI prevalence among pregnant women with published work which was carried out in 1999 at the same clinics as the current study [18]. A significant decline in curable RTIs was observed, especially for syphilis (from 3.4% to 0.9%; p = 0.001), trichomoniasis (from 23.4% to 5.0%; p < 0.001) and bacterial vaginosis (from 31.4% to 20.9%; p = 0.001). No significant decrease was observed in the prevalence of HSV-2 infection.

**Discussion**

In this study viral infections (HSV-2 and HIV) are more common than the curable non-viral STIs like trichomoniasis, syphilis or gonorrhoea [14,16,17]. We also noted a decline of curable genital tract infections among pregnant women between 1999 and 2004. A high prevalence of HSV-2 and decreasing prevalence of curable genital tract infections like syphilis, chlamydia, gonorrhoea, trichomoniasis and bacterial vaginosis has been reported in several sub-Saharan countries among pregnant women [15,22,23], among women in the general population [23], and among women in high risk groups [16,17,23]. The introduction of and scaling up of syndromic approach for management of STIs in most primary health clinics may partly explain the decrease [6,23]. The change in the genital infection spectrum however, highlights the need to strengthen STI surveillance, so as to be able to adjust syndromic management protocols according to the epidemiological situation.

Despite the declining trend, the prevalence of trichomoniasis (5%) and bacterial vaginosis (20.9%) are still high, considering that this was a pregnant population. Untreated, trichomoniasis (TV) has been associated with preterm birth and low birth weight (LBW), while bacterial vaginosis (BV) can cause preterm rupture of membranes, preterm birth, LBW and postpartum sepsis especially in women with a previous history of preterm delivery [2]. Prematurity and low birth weight are among the leading causes of perinatal morbidity and mortality in resource-poor settings [1,2,10]. Studies have also indicated that both BV and TV may increase the risk of HIV acquisition, and BV may have an effect on mother-to-child transmission of HIV [10-12]. Efforts are thus required to treat these vaginal infections in pregnancy. An approach like presumptive treatment (mass treatment on the presumption that the disease might be present) has been associated with significant reduction in the prevalence of these infections, and in the incidence of LBW, early neonatal death and preterm delivery [4].

The active syphilis prevalence of 0.9% was similar to that reported for women in the general population (0.2%) or among bar workers (1.1%) in the same district [14,17]. However it was lower than in pregnant women in the Mwanza (7.7%), Mbeya (4.1%) and Kagera (14.9%) regions in Tanzania, and among pregnant women in Uganda (3.3%), Zimbabwe (3.4%), Mozambique (4.7%) and Cameroon (13%), showing variation within and between countries in Africa [3-6,15,22,24]. Our results however might be an underestimation in the prevalence of syphilis because women with early foetal loss resulting
from syphilis would not be represented, since we recruited women in the third trimester [3]. Lumbiganon et al (2002) showed that even with a low background prevalence of 0.9%, women with syphilis had significantly more adverse pregnancy outcomes e.g. LBW and perinatal death [25]. Syphilis screening and treatment in pregnancy is thus cost-effective even at prevalences < 1% and supports the WHO recommendation to perform serological screening on all pregnant women at first visit [1]. With resources being mobilized for expansion of prevention of...
mother-to-child transmission of HIV programs in most sub-Saharan African countries, this opportunity should be used to expand syphilis screening and treatment at the same time.

The higher prevalence of STIs and bacterial vaginosis among HIV-seropositive women than seronegative women has also been reported among pregnant women in Zimbabwe, Cameroon, Thailand and USA [5,8,24]. HIV-infected people have higher rates of genital infection probably because of shared behavioral risk factors that facilitate transmission of both infections [7], or increased susceptibility to some RTIs like gonorrhoea and GUD, especially with advanced immune suppression [26]. RTIs in HIV-infected women has been associated with more severe adverse reproductive health outcomes than in uninfected women, including pelvic inflammatory disease, high grade cervical intraepithelial lesions, postpartum endometritis, preterm birth and neonatal death [2,24,25]. Also, the presence of bacterial vaginosis, candidiasis, trichomoniasis, gonorrhoeae, chlamydia and HSV-2 in HIV-infected women, increases HIV genital shedding, thus an increased concentration of HIV in genital secretions [9,10,28,29]. Increased infectiousness increases the risk of both vertical and sexual HIV transmission. In fact, studies have recently shown that bacterial vaginosis, chorioamnionitis, genital ulcers and HSV-2 are associated with increased rates of mother-to-child HIV transmission [8,10,30,31]. Efforts to expand HIV-counseling and testing services to all centers offering antenatal care is vital in order to identify HIV-infected women. Apart from offering antiretroviral therapy (ART) to reduce perinatal HIV

| Table 2: Prevalence of laboratory confirmed reproductive tract/sexually transmitted infections by HIV status among pregnant women in Moshi, Tanzania |
|-----------------------------------------------|
| Serology                                      |
| HIV-1                                         |
| 184/2654                                      |
| 6.9%                                          |
| Active syphilis                               |
| 23/2654                                       |
| 0.9%                                          |
| 3.3%                                          |
| 0.7% **                                       |
| HSV-2                                         |
| 427/1271                                      |
| 33.6%                                         |
| 43.2%                                         |
| 32.0% **                                      |
| Chlamydia trachomatis                         |
| 183/1048                                      |
| 17.5%                                         |
| 30.0%                                         |
| 16.6% **                                      |
| Cervical & vaginal STIs/RTIs                  |
| Neisseria gonorrhoea                          |
| 13/2555                                       |
| 0.5%                                          |
| 1.6%                                          |
| 0.4% *                                        |
| Trichomonas vaginalis                        |
| 129/2555                                      |
| 5.0%                                          |
| 7.1%                                          |
| 4.9%                                          |
| Bacterial vaginosis                           |
| 533/2555                                      |
| 20.9%                                         |
| 37.2%                                         |
| 19.6% **                                      |
| Candida albicans                              |
| 292/2555                                      |
| 11.4%                                         |
| 14.2%                                         |
| 11.2%                                         |
| Any vaginal infection¶                        |
| 754/2555                                      |
| 29.5%                                         |
| 46.4%                                         |
| 28.2% **                                      |
| Clinical STIs                                 |
| Genital ulcer                                 |
| 41/2555                                       |
| 1.6%                                          |
| 4.4%                                          |
| 1.4% *                                        |
| Genital warts                                 |
| 11/2555                                       |
| 0.4%                                          |
| 1.1%                                          |
| 0.4%                                          |
| Any curable STI #                             |
| 162/2558                                      |
| 6.3%                                          |
| 11.5%                                         |
| 5.9% **                                       |
| Any curable STI/RTI †                         |
| 633/2558                                      |
| 24.7%                                         |
| 43.2%                                         |
| 23.3% **                                      |

¶ Trichomoniasis, bacterial vaginosis or candidiasis.
# Syphilis, gonorrhoea, trichomoniasis.
* p ≤ 0.05, ** p < 0.01, *** p < 0.001
transmission, the women should also be offered screening for genital tract infections. Treatment of genital infection significantly lowers genital HIV concentrations [9,10,28,29], thus treatment of maternal genital infections in HIV-infected women during pregnancy may substantially reduce negative reproductive effects on the women themselves, may reduce sexual HIV transmission and play a part in reducing mother-to-child transmission. Efforts to address RTIs in HIV-infected women should not be limited to pregnancy but should also be extended to ART care clinics.

There may be possible limitations in the study regarding some of the laboratory tests used to diagnose RTIs. Culture and microscopy were used to diagnose gonorrhoeae and trichomoniasis in this study. Nucleic acid amplification technology using polymerase chain reaction (PCR) has been shown to have a higher sensitivity and specificity than culture and microscopy for identification of both gonorrhoea and trichomoniasis [32,33]. The traditional tests used might have thus missed a substantial proportion of these infections. Further, we used an IgG antibody test to diagnose Chlamydia trachomatis. This test can only show the proportion of women who had been exposed to the Chlamydia infection in the past. It cannot differentiate between women with active and with past infections. Therefore it may be used only for epidemiological studies and not for diagnosing women for treatment.

Despite the possible limitations, the study has demonstrated that STIs and other reproductive tract infections are still prevalent among pregnant women in the area. Routine screening and treatment during antenatal care is recommended. HIV-infected women should receive adequate screening for genital tract infections during pregnancy. Future research and public health preventive efforts should target not only the classical bacterial RTIs but also HSV-2 as it was the most prevalent STI. Lastly, studies using more sensitive assays (PCR) for screening STIs during pregnancy are required, in order to give a more precise picture of STI occurrence.

### Competing interests
The authors declare that they have no competing interests.

### Authors’ contributions
SEM designed the study, recruitment of participants, collected and entered data, analyzed data and drafted the
manuscript. JU participated in data collection, laboratory testing and data analysis, revising the drafted manuscript. AH conception, design, analysis and reviewed the drafted manuscript. EM designed the study, participated in analysis and interpretation, reviewed the drafted manuscript. SJ design of laboratory testing, chlamydia testing, interpretation of results. NES designed the study, supervised laboratory testing, reviewed the drafted manuscript. BSP conception, design, coordinated the study, interpreted data and reviewed the drafted manuscript. All authors read and approved the manuscript.

Acknowledgements
The authors thank the participating women for their time, the team of nurses and laboratory staff at Majengo and Pasua clinics for their hard work, and Robert K Stallman for review of the manuscript. This study was supported by a grant from the Letten Foundation. Wijgert JH van de, Morrison CS, Cornelisse PG, Mbabbo L, Mmbando D, Maboko L, Riedner G, Hoffmann O, Rusizoka M, Mbizvo EM, Msuya SE, Stray-Pedersen B, Sundby J, Chirenje ZM, Hussain A, Lumbiganon P, Piaggio G, Villar J, Pinol A, Bakketeig L, Bergsjø P, Al-Tawil T, Awio P, Wang J, Pol B Van der, Chipato T, Salata RA, Padian NK, Lohman-Payne BL, Ashley-Morrow R, Corey L, Farqu

References
1. World Health Organization: Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates Geneva: WHO; 2001.
2. Mullick S, Watson-Jones D, Beksińska M, Mabey D: Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. Sex Transf Infect 2005, 81:294-302.
3. Watson-Jones D, Changaliala J, Gumodoka B, Weiss H, Rusizoka M, Ndieli L, Whitehouse A, Balira R, Todd J, Ngela GS, Ross D, Buve A, Hailu M, Mabey D: Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. J Infect Dis 2002, 186:940-947.
4. Gray RH, Wabwire-Mangen F, Kigozi G, Sewankambo N, Serwadda D, Moulton L, Quinn T, O'Brien K, Meehan M, Abramowsky C, Robb M, Wawer M: Randomised trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet Gynecol 2001, 185:1209-1217.
5. Mbizo EM, Msuya SE, Stray-Pedersen B, Sundby J, Chirenje ZM, Hus

Manuscript cleansing, increase HIV-1 infection in African women. J Acquir Immune Defic Syndr 2008, 48(2):203-210.

7. Lobmaia G, Klouman A, Leya J, Masenga E, Sam N, Msiyika K, Klepp K: Incidence of HIV-1 infection and changes in the prevalence of reproductive tract infection and sexual risk behaviours: a population based longitudinal study in rural Tanzania. AJAR 2006, 5(3):281-287.

8. Kage SH, Sam NE, Mbabbo L, Ballard RC, Shao JL, Larsen U: The epidemiology of HIV-1 infection in northern Tanzania: results from a community-based study. AIDS Care 2006, 18(4):379-87.

9. Jordan-Harder B, Maboko L, Mbinda D, Riedner G, Nagale E, Harder J, Kuchen V, Kilian A, Korte R, Sonnenburg F: Thirteen years HIV-1 sentinel surveillance and indicators for behavioural change suggest impact of programme activities in south-west Tanzania. AIDS 2004, 18:287-294.

10. Riedner G, Hoffmann O, Rusizoka M, Mbinda D, Maboko L, Giaguido H, Todd J, Hayes H, Hoelscher M: Decline in sexually transmitted infection prevalence and HIV incidence in female barworkers attending prevention and care services in Mbeya region, Tanzania. AIDS 2006, 20:609-615.

11. Ao TT, Sam NE, Masenga E, Chirenje ZM, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

12. National Bureau of Statistics (NBS) ORC Macro: Tanzania Demographic and Health Survey 2004–2005 Dar es Salaam, Tanzania: National Bureau of Statistics and ORC Macro; 2005.

13. Msuya SE, Mbizo EM, Stray-Pedersen B, Sundby J, Sam NE, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

14. Ao TT, Sam NE, Masenga E, Chirenje ZM, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

15. Riedner G, Hoffmann O, Rusizoka M, Mbinda D, Maboko L, Giaguido H, Todd J, Hayes H, Hoelscher M: Decline in sexually transmitted infection prevalence and HIV incidence in female barworkers attending prevention and care services in Mbeya region, Tanzania. AIDS 2006, 20:609-615.

16. Ao TT, Sam NE, Masenga E, Chirenje ZM, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

17. Ao TT, Sam NE, Masenga E, Chirenje ZM, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

18. Ao TT, Sam NE, Masenga E, Chirenje ZM, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

19. Ao TT, Sam NE, Masenga E, Chirenje ZM, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

20. Msuya SE, Mbizo EM, Stray-Pedersen B, Sundby J, Sam NE, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

21. Ao TT, Sam NE, Masenga E, Chirenje ZM, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

22. Msuya SE, Mbizo EM, Stray-Pedersen B, Sundby J, Sam NE, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

23. Ao TT, Sam NE, Masenga E, Chirenje ZM, Hussain A: Reproductive tract infections among women attending primary health care facilities in Moshi, Tanzania. East Afr Med J 2002, 79:16-21.

24. Lumbiganon P, Piaggio G, Villar J, Pinol A, Bakketeig L, Bergsjo P, Al-

25. Mbu E, Kongnyuy E, Mbopi-Keou FX, Tonye R, Nana P, Leke R: Contribution of HIV-1 infection to maternal and perinatal outcomes, and approach to treatment in developing countries. Sex Transf Infect 1999, 75:3-17.

26. Bollen LJ, Whiteshed SJ, Mock PA, Leelawiwat W, Masenga E, Sam N, Msiyika K, Klepp K: Incidence of HIV-1 infection and changes in the prevalence of reproductive tract infection and sexual risk behaviours: a population based longitudinal study in rural Tanzania. AJAR 2006, 5(3):281-287.

27. Kamenga M, De Cook K, St Louis J, Toure C, Zakaria S, N’gbichi JM, Defer MC, Djagbare D, Sanon A, Andonaba JB, Becquart P, Segondy M, Vallo R, Sawadogo A, Perre P Van de. Review of STI and HIV epidemiological data from 1990 to 2001 in urban Burkina Faso: implications for STI and HIV control. Sex Transm Infect 2004, 80:S12-49.

28. Wang CC, McClleland RS, Reilly M, Overbaugh J, Emery SR, Mandaliya K, McClleland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Pan-

29. McClleland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panc-

30. Drake AL, John-Stewart GC, Wald A, Mbior-Ngasha DA, Bosire R, Wamalwa DC, Lohman-Payne BL, Ashley-Morrow R, Corey L, Farqu
Herpes simplex virus type 2 risk and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 2007, 109:403-409.

31. Chi B, Mudenda V, Levy J, Sinkala M, Goldenberg RL, Stringer JS: Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-I transmission. Am J Obstet Gynecol 2006, 194(1):174-181.

32. Wendel KA, Erbelding EJ, Gaydos CA, Rompalo AM: Trichomonas vaginalis polymerase chain reaction compared to standard diagnostic and therapeutic tools for detection and treatment of vaginal trichomoniasis. Clin Infect Dis 2002, 35:576-80.

33. Knox J, Tabrizi SN, Miller P, Petoumenos K, Law M, Chen S, Garland SM: Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by polymerase chain reaction among women living in remote areas. Sex Transm Dis 2002, 29(11):647-54.